Success Stories: NAILG Wins NIW Approval in Just 27 Days for a Researcher in Epidemiology from Denmark, Thanks to Premium Processing Upgrade

 

Client’s Testimonial:

“Thanks to NAILG for their exceptional service, I was able to achieve NIW approval in just 27 days. I highly recommend their services.”

---

On February 8^th, 2023, we received another EB-2 NIW (National Interest Waiver) approval for a Researcher in the Field of Epidemiology (Approval Notice).

---

General Field: Epidemiology

Position at the Time of Case Filing: Researcher

Country of Origin: Denmark

State of Residence at the Time of Filing: California

Approval Notice Date: February 8^th, 2023

Processing Time: 27 days (Premium Processing Requested)

---

Case Summary:

When an expert researcher from Denmark working in the field of epidemiology approached us at NAILG for his National Interest Waiver application, we made sure that his case won approval as quickly as possible. Recently the USCIS has allowed premium processing (PP) for EB2-NIW cases as well. This has facilitated quick adjudication of cases such as that of the present client. USCIS adjudicates their I-140 NIW petitions within 45 calendar days.

Continuing with our precedent, we began working with him to build a solid petition that would go on to win approval in just 27 days, thanks to the premium processing upgrade.

Some of the other factors that played a role in this approval are as follows:

• His proposed endeavor was to work on his research developing new diagnostic and treatment selection tools in order to optimize diagnostics and treatments for cancer.
• This research was of great importance because it provides essential improvements in diagnostic and treatment selection tools for cancer, which is a global health threat. Overall, his research forms an integral component of the larger global effort into developing tools for optimized cancer diagnostics and treatment in order to reduce mortality rates and improve prognosis through accurate diagnosis and effective personalized treatments.
• His proposed endeavor also had broad implications for the United States since cancer is a leading national concern in the United States with an estimated 1.9 million new cancer cases and over 600,000 cancer deaths in 2022. His research developing new diagnostic and treatment selection tools for cancers, such as prostate cancer, therefore directly addresses health concerns in the United States through improved prognosis due to advanced cancer technologies and knowledge.
• Due to its clear national importance, his research has in fact been supported with funding from the National Institutes of Health (NIH), the Danish Cancer Society, and directly from the National Cancer Institute (NCI).
• Not only this but his petition was bolstered by letters of recommendation from experts who understood the value of his work, one of whom said the following:

“[The client’s] work in bolstering prostate segmentation for biopsy is a crucial portion of the fight against prostate cancer. His methods make prostate biopsies a more accurate procedure that is more easily accomplished by physicians. His research, accordingly, is an important part of continuing to achieve better American prostate cancer care outcomes.”

• He has also completed at least 80 reviews to date and his research has resulted in 15 peer-reviewed journal articles (2 of them first-authored), 2 peer-reviewed conference papers, and 2 invited publications (1 of them first-authored) which have been cited a total of 164 times according to Google Scholar.
• Furthermore, he has pursued research directly related to his proposed endeavor of developing new diagnostic and treatment selection tools in order to optimize diagnostics and treatments for cancer for 3 years.

All of these factors combined, made for an impressive petition and led to the victory of this case. We are privileged to have had the opportunity to work with him and we wish him the very best in his future endeavors.

---